Biofunctionalized Nanomaterials: Alternative for Encapsulation Process Enhancement

Razura-Carmona, Francisco Fabián; Pérez-Larios, Alejandro; Sáyago-Ayerdi, Sonia G.; Herrera-Martínez, Mayra; Sánchez-Burgos, Jorge Alberto

doi:10.3390/polysaccharides3020025

Cited by 3 publications

(1 citation statement)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, in vitro cell tests allow checking of the cellular environment and homogeneity, both morphologically and compositionally. This provides a deeper understanding of the biological and biochemical processes that occur during treatments ( Razura-Carmona et al, 2022 ). L929 mouse fibroblast was used for in vitro cytotoxicity testing in this study.…”

Section: Resultsmentioning

confidence: 99%

In vitroandin silicoevaluation of the design of nano-phyto-drug candidate for oral use againstStaphylococcus aureus

Budama‐Kilinc

Gök

Aluc

et al. 2023

PeerJ

View full text Add to dashboard Cite

Onopordum acanthium is a medicinal plant with many important properties, such as antibacterial, anticancer, and anti-hypotensive properties. Although various studies reported the biological activities of O. acanthium, there is no study on its nano-phyto-drug formulation. The aim of this study is to develop a candidate nano-drug based on phytotherapeutic constituents and evaluate its efficiency in vitro and in silico. In this context, poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) of O. acanthium extract (OAE) were synthesized and characterized. It was determined that the average particle size of OAE-PLGA-NPs was 214.9 ± 6.77 nm, and the zeta potential was −8.03 ± 0.85 mV, and PdI value was 0.064 ± 0.013. The encapsulation efficiency of OAE-PLGA-NPs was calculated as 91%, and the loading capacity as 75.83%. The in vitro drug release study showed that OAE was released from the PLGA NPs with 99.39% over the 6 days. Furthermore, the mutagenic and cytotoxic activity of free OAE and OAE-PLGA-NPs were evaluated by the Ames test and MTT test, respectively. Although 0.75 and 0.37 mg/mL free OAE concentrations caused both frameshift mutation and base pair substitution (p < 0.05), the administered OAE–PLGA NP concentrations were not mutagenic. It was determined with the MTT analysis that the doses of 0.75 and 1.5 mg/mL of free OAE had a cytotoxic effect on the L929 fibroblast cell line (p < 0.05), and OAE-PLGA-NPs had no cytotoxic effect. Moreover, the interaction between the OAE and S. aureus was also investigated using the molecular docking analysis method. The molecular docking and molecular dynamics (MD) results were implemented to elucidate the S. aureus MurE inhibition potential of OAE. It was shown that quercetin in the OAE content interacted significantly with the substantial residues in the catalytic pocket of the S. aureus MurE enzyme, and quercetin performed four hydrogen bond interactions corresponding to a low binding energy of −6.77 kcal/mol with catalytic pocket binding residues, which are crucial for the inhibition mechanism of S. aureus MurE. Finally, the bacterial inhibition values of free OAE and OAE–PLGA NPs were determined against S. aureus using a microdilution method. The antibacterial results showed that the inhibition value of the OAE–PLGA NPs was 69%. In conclusion, from the in vitro and in silico results of the nano-sized OAE-PLGA NP formulation produced in this study, it was evaluated that the formulation may be recommended as a safe and effective nano-phyto-drug candidate against S. aureus.

show abstract

Section: Resultsmentioning

confidence: 99%

In vitroandin silicoevaluation of the design of nano-phyto-drug candidate for oral use againstStaphylococcus aureus

Budama‐Kilinc

Gök

Aluc

et al. 2023

PeerJ

View full text Add to dashboard Cite

show abstract

Biomimetic and Bioinspired Nanostructures

Chakraborty

Bera

Roy³

et al. 2023

Bioinspired and Green Synthesis of Nanostructures

View full text Add to dashboard Cite

Biogenic Silica for Drug Delivery and Gene Therapy

Ahmed,

Das,

Samanta

et al. 2024

Biogenic Silica

View full text Add to dashboard Cite

Biogenic silica (BS) is widely employed in numerous applications including medical diagnosis, gene therapy, drug delivery as well as in the food industry and several synthetic processes with their large surface area, controllable particle size, and great biocompatibility. Using some convenient and affordable methods help to develop BS, fabricated via fundamental green approaches. Some research has evaluated the biomedical aspects of BS along with the surface functionalization and structural modification to specially address various cancers as well as medical disorders. On the other hand, research on in vivo and in vitro toxicity of BS is still in exploratory stages, and its toxicity mechanisms are not clearly understood. This book chapter covers current research on the biological uses of BS such as the usage in photonic applications, gene therapy, drug delivery systems and the detection or treatment of numerous diseased conditions. This book chapter also discusses fundamental advancements and exploratory development of BS in the research field that could eventually become a practical expansion in future biomedical application.

show abstract

Biofunctionalized Nanomaterials: Alternative for Encapsulation Process Enhancement

Cited by 3 publications

References 76 publications

In vitroandin silicoevaluation of the design of nano-phyto-drug candidate for oral use againstStaphylococcus aureus

In vitroandin silicoevaluation of the design of nano-phyto-drug candidate for oral use againstStaphylococcus aureus

Biomimetic and Bioinspired Nanostructures

Biogenic Silica for Drug Delivery and Gene Therapy

Contact Info

Product

Resources

About